×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XOMA – xoma royalty corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XOMA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/7
07:30 am
xoma
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Low
Report
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
10/23
08:18 am
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
Low
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
10/22
08:00 am
xoma
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
Low
Report
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
9/23
06:30 am
xoma
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
Low
Report
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
9/23
05:30 am
xoma
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Low
Report
XOMA Royalty Declares Quarterly Preferred Stock Dividends
9/20
01:29 pm
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
Medium
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
9/4
07:30 am
xoma
XOMA Royalty to Present at Upcoming Investor Conferences in September
Medium
Report
XOMA Royalty to Present at Upcoming Investor Conferences in September
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/13
06:55 pm
xoma
Form 4 XOMA Royalty Corp For: Nov 11 Filed by: BURNS THOMAS M.
Low
Report
Form 4 XOMA Royalty Corp For: Nov 11 Filed by: BURNS THOMAS M.
11/13
06:55 pm
xoma
Form 4 XOMA Royalty Corp For: Nov 11 Filed by: Hughes Owen
Low
Report
Form 4 XOMA Royalty Corp For: Nov 11 Filed by: Hughes Owen
11/7
07:46 am
xoma
Form 8-K XOMA Royalty Corp For: Nov 07
Low
Report
Form 8-K XOMA Royalty Corp For: Nov 07
11/7
07:36 am
xoma
Form 10-Q XOMA Royalty Corp For: Sep 30
Low
Report
Form 10-Q XOMA Royalty Corp For: Sep 30
10/22
08:16 am
xoma
Form 8-K XOMA Royalty Corp For: Oct 21
Low
Report
Form 8-K XOMA Royalty Corp For: Oct 21
9/23
06:35 am
xoma
Form 8-K XOMA Royalty Corp For: Sep 20
Low
Report
Form 8-K XOMA Royalty Corp For: Sep 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/20
XOMA Announces Closing of Rights Offering
13.4%
3/23 Form 4 XOMA Corp For: Mar 20 Filed by: Neal James R 10.7%
11/5 Q3/2019 9/30/2019 EPS 0.200 ZacksConsensus -0.480 ActVsEst 0.680 - Beat 7.3%
3/16 Form 4 XOMA Corp For: Mar 13 Filed by: Neal James R 7.3%
2/13 Form SC 13D/A XOMA Corp Filed by: BIOTECHNOLOGY VALUE FUND L P 6.7%
3/27 Form 4 XOMA Corp For: Mar 25 Filed by: BVF PARTNERS L P/IL 6.2%
5/14 Form 4 XOMA Corp For: May 10 Filed by: VAN NESS W DENMAN 5.9%
12/5 Iscalimab (CFZ533) Update 4.9%
5/20 Form 4 XOMA Corp For: May 16 Filed by: Kosacz Barbara 3.6%
2/15 XOMA Corp (NASDAQ: XOMA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.3%
3/23 Form 4 XOMA Corp For: Mar 20 Filed by: Neal James R 10.7%
11/5 Q3/2019 9/30/2019 EPS 0.200 ZacksConsensus -0.480 ActVsEst 0.680 - Beat 7.3%
3/16 Form 4 XOMA Corp For: Mar 13 Filed by: Neal James R 7.3%
2/13 Form SC 13D/A XOMA Corp Filed by: BIOTECHNOLOGY VALUE FUND L P 6.7%
3/27 Form 4 XOMA Corp For: Mar 25 Filed by: BVF PARTNERS L P/IL 6.2%
5/14 Form 4 XOMA Corp For: May 10 Filed by: VAN NESS W DENMAN 5.9%
12/5 Iscalimab (CFZ533) Update 4.9%
5/20 Form 4 XOMA Corp For: May 16 Filed by: Kosacz Barbara 3.6%
2/15 XOMA Corp (NASDAQ: XOMA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.3%
TOP News Decliners
3/14
XOMA Corp (NASDAQ: XOMA) had its "hold" rating re-affirmed by analysts at Zacks Investment Research.
-16.4%
3/17 Form 3 XOMA Corp For: Mar 13 Filed by: BVF GP HOLDINGS LLC -10.6%
5/6 Form 10-Q XOMA Corp For: Mar 31 -8.5%
5/24 XOMA Corp (NASDAQ: XOMA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -7.7%
3/10 XOMA Corp (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock. -6.2%
2/22 XOMA Corp (NASDAQ: XOMA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.1%
3/9 Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement -5.7%
8/6 Form 8-K XOMA Corp For: Aug 06 -5.7%
9/20 Form 4 XOMA Corp For: Sep 18 Filed by: Neal James R -4.9%
11/19 XOMA Announces Proposed Rights Offering -4.1%
3/17 Form 3 XOMA Corp For: Mar 13 Filed by: BVF GP HOLDINGS LLC -10.6%
5/6 Form 10-Q XOMA Corp For: Mar 31 -8.5%
5/24 XOMA Corp (NASDAQ: XOMA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -7.7%
3/10 XOMA Corp (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock. -6.2%
2/22 XOMA Corp (NASDAQ: XOMA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.1%
3/9 Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement -5.7%
8/6 Form 8-K XOMA Corp For: Aug 06 -5.7%
9/20 Form 4 XOMA Corp For: Sep 18 Filed by: Neal James R -4.9%
11/19 XOMA Announces Proposed Rights Offering -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: